🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Estamos cerca. UroTarget 2024 / 31 Oct-2 Nov. Mendoza, ARG Asociación Argentina de Oncología Clínica (AAOC) UroTarget

Great times with great friends after #gureview2024 LACOG - Latin American Cooperative Oncology Group Laura Bernal Vaca Ray Manneh Kopp. We missed you Maite Bourlon FLoscoMD Enrique Grande

Rock stars! 🚀 LACOG - Latin American Cooperative Oncology Group

No te lo pierdas! Faltan pocos días para uno de los mejores congresos en urooncología UroTarget LACOG - Latin American Cooperative Oncology Group

Enza+Ra223 has a strong evidence in bone mets mCRPC after ADT failure. After Talapro-2 how to choose the best tx for HRR pts? It’ll be important to see the magnitude of benefit and if not all pushed by BRCA pts. We still have a more expensive and toxic combination for tala/enza

Important data from Brazilian Public Health System (#SUS). It’s possible to optimize tx in advanced PC pts to deliver better drugs and treatments. It’s time to rediscuss the cancer treatment pathway in the #SUS and the role of pricing drugs in 🇧🇷 Ministério da Saúde 🩵 Ministério da Ciência, Tecnologia e Inovação Lula

So proud to be part of this huge effort and colaboration. Thank you #Aron family! Prostate Cancer Foundation Kidney Cancer LACOG - Latin American Cooperative Oncology Group Matteo Santoni Francesco Massari Fernando Sabino, MD, PhD

Interesting data! Congrats my friends for another important work!

Aron-3 RWE confirm the efficacy of apalutamide in clinical practice for #mHSPC ARON project

🚨 this is not an IO-naive trial! 🚨 And we all known that nivo/ipi isn’t a good choice for ICI progressors

Is the time-of-day matters for #mRCC patients receiving ICI?

Which impact of time-of-day administration of immunotherapy on survival in metastatic #rcc ? Out now our meta-analysis ⁦Fernando Sabino, MD, PhD⁩ ⁦Andrey Soares⁩ ⁦veronica mollica⁩ ⁦Matteo Santoni⁩ link.springer.com/article/10.100…

Is ICI+TKI better than Sunitinib in fav-risk #mRCC? In the abscense of biomarkers, this RWE gives us some insights into which patient should receive each treatment Fernando Sabino, MD, PhD Francesco Massari Matteo Santoni Javier Molina Cerrillo ARON project

What should we measure, and how should we measure it? A fundamental question.

Great data, but not much different from #PEACE3 trial, with more toxicity. Would like to see the subsequent treatment accordingly with HRR status and a deep molecular analysis in the HRR -ve/unknown populatiom #GU25

Would be very informative see the data of non-progressive patients who discontinue therapy versus patients with continuous therapy #GU25

CM274 is a negative trial, even in the #MIBC pts 1. Statistically negative in ITT and MIBC 2. Around 50% of pts did not received chemo and only 26% of them received ICI in the progression 3. The remaining pts received GC x 4 3. Higher cost and acute and chronic tx #GU25

OS benefit driven by non-responders patients. There are many censoring in the responders curves, and no data about subsequent therapy. We must discuss carefully adjuvant phase in pCR patients. #GU25